TABLE 3.
Treatment of CMV, and outcomes of treatment
| BMT/Oncology (N = 6) | SOT (N = 10) | Total (N = 16) | |
|---|---|---|---|
| Treated with GCV/VGCV before CDV | 6 (100%) | 10 (100%) | 16 (100%) |
| Treated with FOS before CDV | 5 (83.3%) | 4 (40%) | 9 (56.3%) |
| Median time to CDV after first CMV+ (d) | 90 (IQR 43–230.75) | 112 (IQR 21–154) | 112 (IQR 38–152) |
| Median duration CDV received (d) | 30 (IQR 15.25–68.25) | 16 (IQR 8–35.5) | 21.5 (IQR 8.3–47.3) |
| Median number of CDV doses received | 3 (IQR 2–10) | 2 (IQR 1–4) | 3 (IQR 1–4) |
| CDV dosing schedule weekly × 2 doses then every 2 wka | 1 | 3 | 4 |
| CDV dosing schedule weeklya | 5 | 7 | 12 |
| CMV Immune globulin received | 5 (83.3%) | 3 (30%) | 8 (50%) |
| GCV/VGCV given after CDV therapy | 2 (33.3%) | 3 (30%) | 5 (31.3%) |
| Uveitis | 1 (16.7%) | 3 (30%) | 4 (25%) |
| Nephrotoxicityb | 3 (50%) | 3 (30%) | 6 (37.5%) |
| Recovery of renal functionc | 0 | 1 (10%) | 1 (6.3%) |
| Failure to clear CMV DNAemiad | 4 (66.7%) | 4 (40%) | 8 (50%) |
| Deathe | 4 (66.7%) | 4 (40%) | 8 (50%) |
| Median time to death (days) for patients who died (4 BMT, 4 SOT) | 667.5 (range, 13–2606) | 28.5 (range 21–53) | 33.5 (IQR 22–988) |
Abbreviations: CDV, cidofovir; FOS, foscarnet; GCV/VGCV, GCV, ganciclovir; VGCV, valganciclovir.
a
Listed as weekly if only two doses were received, 1 wk apart.
b
A 1.5× rise in creatinine from start to end of CDV therapy.
c
Recovery to eGFR at time CDV was started, or improved eGFR at 6 months after stopping CDV therapy.
d
Failure to clear DNAemia was defined as not having undetectable CMV DNA level on two consecutive evaluations that occur 5 or more days apart.
e
Time to death in days from date of initiation of CDV.